0

Diabetic Neuropathy Drugs Market by Product, and Geography - Forecast and Analysis 2021-2025

  • Published: Jan 2022
  • Pages: 120
  • SKU: IRTNTR72073
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The diabetic neuropathy drugs market share is expected to increase by USD 2.37 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 12.20%.

This diabetic neuropathy drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers diabetic neuropathy drugs market segmentation by product (calcium channel alpha-2-delta ligand, SNRIs and TCAs, and others) and geography (North America, Europe, Asia, and ROW). The diabetic neuropathy drugs market report also offers information on several market vendors, including Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Grunenthal GmbH, Johnson and Johnson Inc., NeuroBo Pharmaceuticals Inc., Novartis AG, and Pfizer Inc. among others.

What will the Diabetic Neuropathy Drugs Market Size be During the Forecast Period?

Diabetic Neuropathy Drugs Market Size

Download the Free Report Sample to Unlock the Diabetic Neuropathy Drugs Market Size for the Forecast Period and Other Important Statistics

 

Diabetic Neuropathy Drugs Market: Key Drivers, Trends, and Challenges

The increasing prevalence of diabetic neuropathy is notably driving the diabetic neuropathy drugs market growth, although factors such as the high cost of treatment may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the diabetic neuropathy drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Diabetic Neuropathy Drugs Market Driver

The increasing prevalence of diabetic neuropathy is one of the key drivers supporting the diabetic neuropathy drugs market growth. Diabetic neuropathy often damages nerves in the feet and legs of an individual. The prevalence of diabetic neuropathy has increased due to the rise in the prevalence of diabetes globally. according to the CDC, in 2021, 50% of people with diabetes had some form of nerve damage. The longer a person has diabetes, the higher is the risk of developing neuropathy. About one-third to one-half of people with diabetes have peripheral neuropathy. About 60%-70% of people with diabetes develop diabetic neuropathy. Thus, such an increase in the number of diabetic neuropathy is driving the market growth.

Key Diabetic Neuropathy Drugs Market Trend

The development of topical patches for the treatment of diabetic neuropathy is another factor supporting the diabetic neuropathy drugs market growth. The traditional approaches for the treatment of neuropathic pain associated with diabetic neuropathy led to many complications, which affected patient compliance. Topical treatments are considered an effective way to treat chronic pain as the current treatments have limited absorption. Also, topical treatments are safer than systemic treatment options. For instance, 5% of topical lidocaine applied as a patch can treat diabetic neuropathy. In May 2009, Qutenza was approved for the treatment of non-diabetic adults with peripheral neuropathy and in September 2015, the license of the drug included diabetic patients as well. Such a rapid increase in the development of tropical patches for the treatment is driving the market growth.

Key Diabetic Neuropathy Drugs Market Challenge

The high cost of treatment is hindering the diabetic neuropathy drugs market growth. The treatment costs of diabetic peripheral neuropathy and its complications can range between $4.6 billion and $13.7 billion in the US annually. As of now, only symptomatic treatment drugs are available for the treatment. The approved drugs for symptomatic treatment are also very few. However, only four branded drugs are available in the market. Such a concentrated market makes it difficult for diabetic neuropathy patients to afford these costly treatments that include overall management of the diabetic neuropathy where drug reimbursement or insurance is difficult. For instance, duloxetine can range from $9.00 to $54.31. Thus, the high cost of drugs used for the treatment of diabetic peripheral neuropathy may hinder the growth of the market during the forecast period.

This diabetic neuropathy drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the diabetic neuropathy drugs market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the diabetic neuropathy drugs market during the forecast period.

Who are the Major Diabetic Neuropathy Drugs Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

  • Alnylam Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly and Co.
  • Grunenthal GmbH
  • Johnson and Johnson Inc.
  • NeuroBo Pharmaceuticals Inc.
  • Novartis AG
  • Pfizer Inc.

 

This statistical study of the diabetic neuropathy drugs market encompasses successful business strategies deployed by the key vendors. The diabetic neuropathy drugs market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

  • AstraZeneca Plc - The company offers neuropathy drugs under the brand name of Bydureon.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The diabetic neuropathy drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Diabetic Neuropathy Drugs Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the diabetic neuropathy drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the pharmaceuticals market  includes the following core components:

  • Research and development (R&D) and drug discovery
  • Integration and product development
  • Manufacturing
  • Outbound logistics
  • Marketing and sales
  • Support services
  • Innovation

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

 

Which are the Key Regions for Diabetic Neuropathy Drugs Market?

Diabetic Neuropathy Drugs Market Market segmentation by region

For more insights on the market share of various regions Request for a FREE sample now!

38% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the diabetic neuropathy drugs market in North America. Market growth in this region will be faster than the growth of the market in ROW.

The growing prevalence of diabetic neuropathy will facilitate the diabetic neuropathy drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

 In 2020, the outbreak of COVID-19 affected all countries in North America, especially the US. It also had a slight negative impact on the diabetic neuropathy drugs market. Some scheduled treatments were either delayed or postponed. Hence, the adoption of diabetic neuropathy drugs declined slightly, which impacted the growth of the regional market in 2020 and Q1 2021 to some extent. However, the imposed restrictions by the half of 2020 may drive the market growth during the forecast period.

What are the Revenue-generating Product Segments in the Diabetic Neuropathy Drugs Market?

Diabetic Neuropathy Drugs Market Segmentation

To gain further insights on the market contribution of various segments Request for a FREE sample

The diabetic neuropathy drugs market share growth by the calcium channel alpha-2-delta ligand segment will be significant during the forecast period. The calcium channel alpha-2-delta ligand segment includes drugs such as pregabalin (LYRICA), gabapentin (NEURONTIN), valproate sodium (Depacon), and carbamazepine (Tegretol). In December 2004, LYRICA was the second agent to be approved by the US FDA to treat neuropathic pain associated with diabetic peripheral neuropathy. Meanwhile, one alpha-2-delta medication has been licensed by the US Food and Drug Administration (FDA) for the treatment of moderate-to-severe RLS. The segment is expected to experience accelerating growth momentum during the forecast period.  

This report provides an accurate prediction of the contribution of all the segments to the growth of the diabetic neuropathy drugs market size and actionable market insights on post COVID-19 impact on each segment.

You may be interested in:

Diabetic Food market - The market share has the potential to grow by USD 3.76 billion during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 6.24%.

Diabetic Foot Ulcers Therapeutics market - The market share is expected to increase by USD 1.74 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 7.01%.

Diabetic Neuropathy Drugs Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 12.20%

Market growth 2021-2025

$ 2.37 billion

Market structure

Fragmented

YoY growth (%)

12.57

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 38%

Key consumer countries

US, Canada, Germany, China, and UK

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Grunenthal GmbH, Johnson and Johnson Inc., NeuroBo Pharmaceuticals Inc., Novartis AG, and Pfizer Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Diabetic Neuropathy Drugs Market Report?

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will drive diabetic neuropathy drugs market growth during the next five years
  • Precise estimation of the diabetic neuropathy drugs market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the diabetic neuropathy drugs industry across North America, Europe, Asia, and ROW
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of diabetic neuropathy drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1. Executive Summary                           

                1.1 Market Overview

                                Exhibit 01:  Key Finding 1

                                Exhibit 02:  Key Finding 2

                                Exhibit 03:  Key Finding 3

                                Exhibit 04:  Key Finding 5

                                Exhibit 05:  Key Finding 6

                                Exhibit 06:  Key Finding 7

                                Exhibit 07:  Key Finding 8

2. Market Landscape                             

                2.1 Market ecosystem             

                                Exhibit 08:  Parent market

                                Exhibit 09:  Market characteristics

                2.2 Value chain analysis           

                                Exhibit 10: Value chain analysis: Pharmaceuticals

                                2.2.1 Research and development (R&D) and drug discovery

                                2.2.2 Integration and product development

                                2.2.3 Manufacturing

                                2.2.4 Outbound logistics

                                2.2.5 Marketing and sales

                                2.2.6 Support services

                                2.2.7 Innovation

3. Market Sizing                       

                3.1 Market definition

                                Exhibit 11:  Offerings of vendors included in the market definition

                3.2 Market segment analysis 

                                Exhibit 12:  Market segments

                3.3 Market size 2020 

                3.4 Market outlook: Forecast for 2020 - 2025 

                                3.4.1 Estimating growth rates for emerging and high-growth markets

                                3.4.2 Estimating growth rates for mature markets

                                Exhibit 13:  Global - Market size and forecast 2020 - 2025 ($ million)

                                Exhibit 14:  Global market: Year-over-year growth 2020 - 2025 (%)

4. Five Forces Analysis                          

                4.1 Five Forces Summary        

                                Exhibit 15:  Five forces analysis 2020 & 2025

                4.2 Bargaining power of buyers           

                                Exhibit 16: Bargaining power of buyers

                4.3 Bargaining power of suppliers       

                                Exhibit 17: Bargaining power of suppliers

                4.4 Threat of new entrants    

                                Exhibit 18: Threat of new entrants

                4.5 Threat of substitutes         

                                Exhibit 19: Threat of substitutes

                4.6 Threat of rivalry   

                                Exhibit 20: Threat of rivalry

                4.7 Market condition

                                Exhibit 21:  Market condition - Five forces 2020

5 Market Segmentation by Product                

                5.1 Market segments

                                Exhibit 22:  Product - Market share 2020-2025 (%)

                5.2 Comparison by Product    

                                Exhibit 23:  Comparison by Product

                5.3 Calcium channel alpha-2-delta ligand - Market size and forecast 2020-2025               

                                Exhibit 24:  Calcium channel alpha-2-delta ligand - Market size and forecast 2020-2025 ($ million)

                                Exhibit 25:  Calcium channel alpha-2-delta ligand - Year-over-year growth 2020-2025 (%)

                5.4 SNRIs and TCAs - Market size and forecast 2020-2025          

                                Exhibit 26:  SNRIs and TCAs - Market size and forecast 2020-2025 ($ million)

                                Exhibit 27:  SNRIs and TCAs - Year-over-year growth 2020-2025 (%)

                5.5 Others - Market size and forecast 2020-2025           

                                Exhibit 28:  Others - Market size and forecast 2020-2025 ($ million)

                                Exhibit 29:  Others - Year-over-year growth 2020-2025 (%)

                5.6 Market opportunity by Product    

                                Exhibit 30:  Market opportunity by Product

6. Customer landscape                         

                6.1 Overview

                                Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria

                                Exhibit 31: ?Customer landscape?

7. Geographic Landscape                     

                7.1 Geographic segmentation

                                Exhibit 32:  Market share by geography 2020-2025 (%)

                7.2 Geographic comparison   

                                Exhibit 33: Geographic comparison

                7.3 North America - Market size and forecast 2020-2025           

                                Exhibit 34:  North America - Market size and forecast 2020-2025 ($ million)

                                Exhibit 35:  North America - Year-over-year growth 2020-2025 (%)

                7.4 Europe - Market size and forecast 2020-2025          

                                Exhibit 36:   Europe - Market size and forecast 2020-2025 ($ million)

                                Exhibit 37:  Europe - Year-over-year growth 2020-2025 (%)

                7.5 Europe - Market size and forecast 2020-2025          

                                Exhibit 38:   Europe - Market size and forecast 2020-2025 ($ million)

                                Exhibit 39:  Europe - Year-over-year growth 2020-2025 (%)

                7.6 ROW - Market size and forecast 2020-2025              

                                Exhibit 40:   ROW - Market size and forecast 2020-2025 ($ million)

                                Exhibit 41:  ROW - Year-over-year growth 2020-2025 (%)

                7.7 Key leading countries        

                                Exhibit 42:  Key leading countries

                7.8 Market opportunity by geography

                                Exhibit 43: Market opportunity by geography

8. Drivers, Challenges, and Trends                   

                8.1 Market drivers     

                                8.1.1 Increasing prevalence of diabetic neuropathy

                                8.1.2 New drug approvals and strong drug pipeline

                                8.1.3 Rising awareness about diabetic neuropathy

                8.2 Market challenges              

                                8.2.1 High cost of treatment

                                8.2.2 Side-effects of major drugs

                                8.2.3 Reimbursement challenges

                                Exhibit 44:  Impact of drivers and challenges

                8.3 Market trends      

                                8.3.1 Development of topical patches for the treatment of diabetic neuropathy

                                8.3.2 Development of digital tools for management of diabetic neuropathy

                                8.3.3 Association between obesity and endocrine disorders

                                8.3.4 Growing focus on emerging economies

9. Vendor Landscape                             

                9.1 Overview

                                Exhibit 45: Vendor landscape

                                The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025. 

                9.2 Landscape disruption        

                                Exhibit 46: ?Landscape disruption?

                                Exhibit 47: Industry risks

                9.3 Competitive landscape     

10. Vendor Analysis               

                10.1 Vendors covered              

                                Exhibit 48: Vendors covered

                10.2 Market positioning of vendors    

                                Exhibit 49: ?Market positioning of vendors?

                10.3 Alnylam Pharmaceuticals Inc.      

                                Exhibit 50:  Alnylam Pharmaceuticals Inc. - Overview

                                Exhibit 51:  Alnylam Pharmaceuticals Inc. - Product and service

                                Exhibit 52:  Alnylam Pharmaceuticals Inc. - Key offerings

                10.4 Astellas Pharma Inc.        

                                Exhibit 53:  Astellas Pharma Inc.  - Overview

                                Exhibit 54:  Astellas Pharma Inc.  - Product and service

                                Exhibit 55:  Astellas Pharma Inc.  - Key offerings

                10.5 AstraZeneca Plc 

                                Exhibit 56:  AstraZeneca Plc - Overview

                                Exhibit 57:  AstraZeneca Plc - Product and service

                                Exhibit 58:  AstraZeneca Plc - Key offerings

                10.6 Daiichi Sankyo Co. Ltd.   

                                Exhibit 59:  Daiichi Sankyo Co. Ltd. - Overview

                                Exhibit 60:  Daiichi Sankyo Co. Ltd. - Business segments

                                Exhibit 61:  Daiichi Sankyo Co. Ltd. - Key offerings

                                Exhibit 62:  Daiichi Sankyo Co. Ltd. - Segment focus

                10.7 Eli Lilly and Co.  

                                Exhibit 63:  Eli Lilly and Co. - Overview

                                Exhibit 64:  Eli Lilly and Co. - Business segments

                                Exhibit 65:  Eli Lilly and Co. - Key offerings

                10.8 Grunenthal GmbH           

                                Exhibit 66:  Grunenthal GmbH - Overview

                                Exhibit 67:  Grunenthal GmbH - Product and service

                                Exhibit 68:  Grunenthal GmbH - Key offerings

                10.9 Johnson and Johnson Inc.              

                                Exhibit 69:  Johnson and Johnson Inc.  - Overview

                                Exhibit 70:  Johnson and Johnson Inc.  - Business segments

                                Exhibit 71:  Johnson and Johnson Inc.  - Key offerings

                                Exhibit 72:  Johnson and Johnson Inc.  - Segment focus

                10.10 NeuroBo Pharmaceuticals Inc.  

                                Exhibit 73:  NeuroBo Pharmaceuticals Inc.  - Overview

                                Exhibit 74:  NeuroBo Pharmaceuticals Inc.  - Product and service

                                Exhibit 75:  NeuroBo Pharmaceuticals Inc.  - Key offerings

                10.11 Novartis AG      

                                Exhibit 76:  Novartis AG - Overview

                                Exhibit 77:  Novartis AG - Business segments

                                Exhibit 78:  Novartis AG - Key offerings

                                Exhibit 79:  Novartis AG - Segment focus

                10.12 Pfizer Inc.          

                                Exhibit 80:  Pfizer Inc. - Overview

                                Exhibit 81:  Pfizer Inc. - Business segments

                                Exhibit 82:  Pfizer Inc. - Key offerings

11. Appendix                            

                11.1 Scope of the report         

                                11.1.1 ????Market definition

                                11.1.2 ????Objectives

                                11.1.3 ????Notes and caveats

                11.2 Currency conversion rates for US$            

                                Exhibit 83: ?Currency conversion rates for US$?

                11.3 Research Methodology 

                                Exhibit 84: ?Research Methodology

                                Exhibit 85: ??Validation techniques employed for market sizing?

                                Exhibit 86: ??Information sources

                11.4 List of abbreviations        

                                Exhibit 87: List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your sample now!
Diabetic Neuropathy Drugs market growth will increase by $2375.27 million during 2020-2025.
The diabetic neuropathy drugs market is expected to grow at a CAGR of 12.20% during 2020-2025.
Technavio has segmented the diabetic neuropathy drugs market by product (Calcium channel alpha-2-delta ligand, SNRIs and TCAs, Others, Calcium channel alpha-2-delta ligand, SNRIs and TCAs, and Others) and geographic (North America, Europe, Asia, and ROW).
Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Grunenthal GmbH, Johnson and Johnson Inc., NeuroBo Pharmaceuticals Inc., Novartis AG, Pfizer Inc. are a few of the key vendors in the diabetic neuropathy drugs market.
North America will register the highest growth rate of 38.01% among the other regions. Therefore, the diabetic neuropathy drugs market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
The key factors driving the diabetic neuropathy drugs market growth are:
  • Increasing prevalence of diabetic neuropathy
The diabetic neuropathy drugs market vendors should focus on grabbing business opportunities from the calcium channel alpha-2-delta ligand segment as it accounted for the largest market share in the base year.
  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?
  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis

Certified ISO 9001 : 2015

We are ISO recognized

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Safe and Secure SSL Encrypted
Technavio

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Customized Report as per your Business Needs

  • Our analysts will work directly with you and understand your needs
  • Get data on specified regions or segments, competitor and Vendors
  • Data will be formatted and presented as per your requirements
  • We offer $1000 worth of FREE customization at the time of purchase

Let us help you make report more suited to your requirements.

  • Get a competitive breakdown as per your niche industry
  • Customize the data with various metrics that meet your business prerequisite
  • Understand Revenue Sources, Customers and many more
  • Details on Market Share
  • These customizations are done in a short amount of time by our analysts and industry experts
Technavio
Enquire Before Buying
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>